Luminex Corporation Stock Price, News & Analysis (NASDAQ:LMNX)

$21.54 0.03 (0.14 %)
(As of 11/21/2017 01:27 AM ET)
Previous Close$21.51
Today's Range$21.39 - $21.74
52-Week Range$17.68 - $22.27
Volume164,700 shs
Average Volume199,883 shs
Market Capitalization$947.61 million
P/E Ratio37.09
Dividend Yield1.12%
Beta0.18

About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.


Industry, Sector and Symbol:
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Life Sciences Tools & Services
  • Sector: Medical
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web: www.luminexcorp.com
Debt:
  • Current Ratio: 5.96%
  • Quick Ratio: 4.61%
Price-To-Earnings:
  • Trailing P/E Ratio: 37.09
  • Forward P/E Ratio: 43.96
  • P/E Growth: 2.7
Sales & Book Value:
  • Annual Sales: $270.64 million
  • Price / Sales: 3.51
  • Cash Flow: $0.78 per share
  • Price / Cash: 27.62
  • Book Value: $9.26 per share
  • Price / Book: 2.33
Dividend:
  • Annual Dividend: $0.24
  • Dividend Yield: 1.1%
Profitability:
  • Trailing EPS: $0.66
  • Net Income: $13.81 million
  • Net Margins: 9.52%
  • Return on Equity: 6.01%
  • Return on Assets: 5.47%
Misc:
  • Employees: 914
  • Outstanding Shares: 44,050,000
 

Frequently Asked Questions for Luminex Corporation (NASDAQ:LMNX)

What is Luminex Corporation's stock symbol?

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex Corporation pay dividends? What is the dividend yield for Luminex Corporation?

Luminex Corporation announced a quarterly dividend on Tuesday, September 12th. Shareholders of record on Friday, September 22nd will be paid a dividend of $0.06 per share on Friday, October 13th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.11%. The ex-dividend date of this dividend is Thursday, September 21st. View Luminex Corporation's Dividend History.

How were Luminex Corporation's earnings last quarter?

Luminex Corporation (NASDAQ:LMNX) issued its quarterly earnings results on Monday, October, 30th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.19 by $0.06. The medical instruments supplier had revenue of $74.14 million for the quarter, compared to analyst estimates of $74.38 million. Luminex Corporation had a net margin of 9.52% and a return on equity of 6.01%. The firm's revenue was up 4.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.21 earnings per share. View Luminex Corporation's Earnings History.

When will Luminex Corporation make its next earnings announcement?

Luminex Corporation is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Luminex Corporation.

Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?

4 analysts have issued twelve-month price objectives for Luminex Corporation's stock. Their predictions range from $18.00 to $21.00. On average, they expect Luminex Corporation's stock price to reach $19.33 in the next twelve months. View Analyst Ratings for Luminex Corporation.

What are Wall Street analysts saying about Luminex Corporation stock?

Here are some recent quotes from research analysts about Luminex Corporation stock:

  • 1. According to Zacks Investment Research, "Luminex’s second quarter saw a strong top line, solid cash flow and soaring profits. The company also beat the Zacks Consensus Estimates on both lines. Luminex’s Assay business is likely to be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory front in the second quarter. In this regard, the recent CE-IVD mark for the ARIES Norovirus Assay,  the FDA approval of ARIES C. difficile Assay and the reimbursement approval of VERIGENE assay in Japan are noteworthy. Luminex is on the verge of completing its clinical study for Group A Strep and is close to submitting the same for FDA review. On the flipside, the company slashed its third-quarter revenue guidance. Luminex expects revenues at the segment to be impacted by funding challenges related to a multi-year bulk bead contract from a life science customer." (8/24/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex Corporation's key competitors?

Who are Luminex Corporation's key executives?

Luminex Corporation's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board (Age 72)
  • Nachum Shamir, President, Chief Executive Officer, Director (Age 63)
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer (Age 55)
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary (Age 49)
  • Todd C. Bennett, Senior Vice President - Global Sales and Customer Operations (Age 47)
  • Nancy M. Fairchild, Senior Vice President - Human resources (Age 63)
  • Tadd S. Lazarus M.D., Senior Vice President (Age 60)
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality (Age 55)
  • Robert J. Cresci, Independent Director (Age 73)
  • Stephen L. Eck, Independent Director (Age 65)

Who owns Luminex Corporation stock?

Luminex Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include Villere ST Denis J & Co. LLC (4.84%), Dimensional Fund Advisors LP (4.13%), Neuberger Berman Group LLC (2.31%), Investment Management of Virginia LLC (2.16%), Elk Creek Partners LLC (1.98%) and Bank of New York Mellon Corp (1.31%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir, Robert J Cresci and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Who sold Luminex Corporation stock? Who is selling Luminex Corporation stock?

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC, GSA Capital Partners LLP, Bank of New York Mellon Corp, Thomson Horstmann & Bryant Inc., JPMorgan Chase & Co., State Board of Administration of Florida Retirement System, Systematic Financial Management LP and Highbridge Capital Management LLC. Company insiders that have sold Luminex Corporation company stock in the last year include G Walter Loewenbaum II and Robert J Cresci. View Insider Buying and Selling for Luminex Corporation.

Who bought Luminex Corporation stock? Who is buying Luminex Corporation stock?

Luminex Corporation's stock was purchased by a variety of institutional investors in the last quarter, including Smith Asset Management Group LP, Elk Creek Partners LLC, Citadel Advisors LLC, Neuberger Berman Group LLC, Investment Management of Virginia LLC, Dimensional Fund Advisors LP, Ameriprise Financial Inc. and American Century Companies Inc.. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

How do I buy Luminex Corporation stock?

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex Corporation's stock price today?

One share of Luminex Corporation stock can currently be purchased for approximately $21.54.

How big of a company is Luminex Corporation?

Luminex Corporation has a market capitalization of $947.61 million and generates $270.64 million in revenue each year. The medical instruments supplier earns $13.81 million in net income (profit) each year or $0.66 on an earnings per share basis. Luminex Corporation employs 914 workers across the globe.

How can I contact Luminex Corporation?

Luminex Corporation's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex Corporation (NASDAQ LMNX)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  334
MarketBeat's community ratings are surveys of what our community members think about Luminex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Luminex Corporation (NASDAQ:LMNX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 1.75)
Consensus Price Target: $19.33 (10.24% downside)

Consensus Price Target History for Luminex Corporation (NASDAQ:LMNX)

Price Target History for Luminex Corporation (NASDAQ:LMNX)

Analysts' Ratings History for Luminex Corporation (NASDAQ:LMNX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Jefferies Group LLCReiterated RatingHold$21.00N/AView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016J P Morgan Chase & CoUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Luminex Corporation (NASDAQ:LMNX)

Earnings by Quarter for Luminex Corporation (NASDAQ:LMNX)

Earnings History by Quarter for Luminex Corporation (NASDAQ LMNX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018$0.13N/AView Earnings Details
10/30/2017Q3 2017$0.19$0.25$74.38 million$74.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09$0.20$75.45 million$76.50 millionViewListenView Earnings Details
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Luminex Corporation (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.22
2018 EPS Consensus Estimate: $0.62
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.03$0.03$0.03
Q4 20171$0.04$0.04$0.04
Q1 20181$0.17$0.17$0.17
Q2 20181$0.15$0.15$0.15
Q3 20181$0.14$0.14$0.14
Q4 20181$0.16$0.16$0.16
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Luminex Corporation (NASDAQ:LMNX)

Most Recent Dividend:10/13/2017
Annual Dividend:$0.24
Dividend Yield:1.11%
Payout Ratio:36.36% (Trailing 12 Months of Earnings)
48.98% (Based on This Year's Estimates)
36.92% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex Corporation (NASDAQ:LMNX)

Dividend History by Quarter for Luminex Corporation (NASDAQ LMNX)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/12/2017Quarterly$0.061.2%9/21/20179/22/201710/13/2017
5/25/2017quarterly$0.061.18%6/21/20176/23/20177/14/2017
2/22/2017special$0.063/22/20173/24/20174/14/2017
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex Corporation (NASDAQ LMNX)

Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 77.54%
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)

Insider Trades by Quarter for Luminex Corporation (NASDAQ LMNX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017G Walter Loewenbaum IIDirectorSell50,000$21.79$1,089,500.00View SEC Filing  
8/23/2017Robert J CresciDirectorSell19,631$18.98$372,596.38View SEC Filing  
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Luminex Corporation (NASDAQ LMNX)

Source:
DateHeadline
Luminex Corporation (LMNX) Expected to Announce Earnings of $0.11 Per ShareLuminex Corporation (LMNX) Expected to Announce Earnings of $0.11 Per Share
www.americanbankingnews.com - November 19 at 11:28 AM
Critical Review: Luminex Corporation (LMNX) and Its CompetitorsCritical Review: Luminex Corporation (LMNX) and Its Competitors
www.americanbankingnews.com - November 18 at 5:12 AM
G Walter Loewenbaum II Sells 50,000 Shares of Luminex Corporation (LMNX) StockG Walter Loewenbaum II Sells 50,000 Shares of Luminex Corporation (LMNX) Stock
www.americanbankingnews.com - November 17 at 1:50 PM
Myriad Genetics' Latest Alliance to Boost GeneSight ReachMyriad Genetics' Latest Alliance to Boost GeneSight Reach
finance.yahoo.com - November 17 at 1:40 PM
Can Luminex Light The Way?Can Luminex Light The Way?
seekingalpha.com - November 15 at 5:08 AM
Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025
finance.yahoo.com - November 15 at 5:08 AM
Luminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare ConferenceLuminex Corporation To Present At The 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 15 at 5:08 AM
BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet EstimatesBioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates
finance.yahoo.com - November 13 at 3:01 PM
Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3
finance.yahoo.com - November 13 at 3:01 PM
ETFs with exposure to Luminex Corp. : November 13, 2017ETFs with exposure to Luminex Corp. : November 13, 2017
finance.yahoo.com - November 13 at 3:01 PM
Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow LessensMedtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens
finance.yahoo.com - November 13 at 3:01 PM
Luminex Corporation (LMNX) Forecasted to Post FY2017 Earnings of $0.49 Per ShareLuminex Corporation (LMNX) Forecasted to Post FY2017 Earnings of $0.49 Per Share
www.americanbankingnews.com - November 13 at 2:58 AM
Luminex Corporation (LMNX) Given Consensus Rating of "Hold" by BrokeragesLuminex Corporation (LMNX) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 12 at 2:16 PM
Myriad Genetics (MYGN) Beats on Q1 Earnings & RevenuesMyriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
finance.yahoo.com - November 8 at 2:17 PM
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
finance.yahoo.com - November 8 at 2:17 PM
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching ClosureVWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
finance.yahoo.com - November 8 at 2:17 PM
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins UpSTERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
finance.yahoo.com - November 3 at 8:04 PM
Omnicell's Higher Investments Drive Costs, Competition RifeOmnicell's Higher Investments Drive Costs, Competition Rife
finance.yahoo.com - November 3 at 8:04 PM
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues MeetDexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
finance.yahoo.com - November 3 at 8:04 PM
First Week of January 2018 Options Trading For LuminexFirst Week of January 2018 Options Trading For Luminex
www.nasdaq.com - November 3 at 3:03 PM
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 GuidancePerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
finance.yahoo.com - November 3 at 3:03 PM
Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat EstimatesAllscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates
finance.yahoo.com - November 3 at 3:03 PM
Bruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View UpBruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View Up
finance.yahoo.com - November 3 at 3:03 PM
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues MissBioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss
finance.yahoo.com - November 3 at 3:03 PM
ETFs with exposure to Luminex Corp. : November 3, 2017ETFs with exposure to Luminex Corp. : November 3, 2017
finance.yahoo.com - November 3 at 3:03 PM
Luminex Corporation (LMNX) Stock Rating Upgraded by TheStreetLuminex Corporation (LMNX) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - November 3 at 7:53 AM
Luminexs (LMNX) CEO Homi Shamir on Q3 2017 Results - Earnings Call TranscriptLuminex's (LMNX) CEO Homi Shamir on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 1 at 5:26 AM
Luminex Corp. (LMNX) Announces FDA Clearance for ARIES Group A Strep AssayLuminex Corp. (LMNX) Announces FDA Clearance for ARIES Group A Strep Assay
www.streetinsider.com - November 1 at 5:26 AM
Luminex Corporation Receives FDA Clearance for ARIES Group A Strep AssayLuminex Corporation Receives FDA Clearance for ARIES Group A Strep Assay
finance.yahoo.com - November 1 at 5:26 AM
Edited Transcript of LMNX earnings conference call or presentation 30-Oct-17 8:30pm GMTEdited Transcript of LMNX earnings conference call or presentation 30-Oct-17 8:30pm GMT
finance.yahoo.com - November 1 at 5:26 AM
$74.24 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter$74.24 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter
www.americanbankingnews.com - October 31 at 1:58 AM
Luminex Corporation Reports Third Quarter 2017 Financial ResultsLuminex Corporation Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 31 at 1:20 AM
Luminex misses 3Q revenue forecastsLuminex misses 3Q revenue forecasts
finance.yahoo.com - October 31 at 1:20 AM
Luminex Corporation (LMNX) Posts  Earnings Results, Beats Expectations By $0.06 EPSLuminex Corporation (LMNX) Posts Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - October 30 at 6:40 PM
Luminex Corporation (LMNX) Scheduled to Post Earnings on MondayLuminex Corporation (LMNX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 23 at 12:52 PM
Jefferies Group Weighs in on Luminex Corporations Q1 2018 Earnings (LMNX)Jefferies Group Weighs in on Luminex Corporation's Q1 2018 Earnings (LMNX)
www.americanbankingnews.com - October 23 at 6:08 AM
Luminex Corporation (LMNX) Receives "Hold" Rating from Jefferies Group LLCLuminex Corporation (LMNX) Receives "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - October 21 at 5:26 PM
Luminex Corporation (LMNX) Receives Average Recommendation of "Hold" from AnalystsLuminex Corporation (LMNX) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - October 18 at 2:48 PM
Heres Why Investors Should Sell Patterson Companies NowHere's Why Investors Should Sell Patterson Companies Now
finance.yahoo.com - October 16 at 8:16 PM
Here's Why Investors Should Sell Patterson Companies NowHere's Why Investors Should Sell Patterson Companies Now
finance.yahoo.com - October 16 at 8:16 PM
Luminex Corporation (LMNX) versus Varian Medical Systems (VAR) Head-To-Head ComparisonLuminex Corporation (LMNX) versus Varian Medical Systems (VAR) Head-To-Head Comparison
www.americanbankingnews.com - October 13 at 2:26 AM
DaVita Banks on Acquisitions, Escalating Expenses a ConcernDaVita Banks on Acquisitions, Escalating Expenses a Concern
finance.yahoo.com - October 9 at 4:30 PM
Luminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017Luminex Corporation Third Quarter Earnings Release Scheduled for October 30, 2017
finance.yahoo.com - October 9 at 4:30 PM
Luminex Corporation (LMNX) vs. ResMed (RMD) Head to Head AnalysisLuminex Corporation (LMNX) vs. ResMed (RMD) Head to Head Analysis
www.americanbankingnews.com - October 8 at 12:22 AM
Financial Survey: Zeltiq Aesthetics (ZLTQ) and Luminex Corporation (LMNX)Financial Survey: Zeltiq Aesthetics (ZLTQ) and Luminex Corporation (LMNX)
www.americanbankingnews.com - October 7 at 6:28 PM
Strategy To YieldBoost LMNX To 9.5% Using OptionsStrategy To YieldBoost LMNX To 9.5% Using Options
www.nasdaq.com - October 6 at 3:36 AM
Bio-Technes New Simple Plex Cartridge Boosts Protein SegmentBio-Techne's New Simple Plex Cartridge Boosts Protein Segment
finance.yahoo.com - September 28 at 6:36 PM
Luminex Corp. – Value Analysis (NASDAQ:LMNX) : September 26, 2017Luminex Corp. – Value Analysis (NASDAQ:LMNX) : September 26, 2017
finance.yahoo.com - September 26 at 5:48 PM
Luminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : September 25, 2017Luminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : September 25, 2017
finance.yahoo.com - September 25 at 8:38 AM
$74.22 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter$74.22 Million in Sales Expected for Luminex Corporation (LMNX) This Quarter
www.americanbankingnews.com - September 24 at 7:54 AM

Social Media

Financials

Chart

Luminex Corporation (NASDAQ LMNX) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.